The 2005 discovery that Philadelphia chromosome-negative myeloproliferative neoplasms, and most prominently polycythemia vera (PV), are associated with activating V671F mutation in JAK2 kinase [212,213], opened the way for development of new strategies based on JAK2-specific antagonists for treatment of these conditions. The gene discussed is JAK2; the disease is acquired polycythemia vera.